Understanding the dose-response is critical for successful drug development. We describe an adaptive design to efficiently learn about the dose-response and the ED95. A dynamic termination rule allows for early discontinuation either for efficacy or futility. The design was deployed in ASTIN, a phase II proof-of-concept trial of the neuroprotectant, neutrophil inhibitory factor (NIF), in acute stroke. We discuss the learning from this trial.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1191/1740774505cn094oa | DOI Listing |
Publication Analysis
Top Keywords
acute stroke
8
astin bayesian
4
bayesian adaptive
4
adaptive dose-response
4
dose-response trial
4
trial acute
4
stroke understanding
4
understanding dose-response
4
dose-response critical
4
critical successful
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!